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Abstract
Background: Hepatitis delta virus (HDV) ribozyme is an attractive molecular tool that can specifically recognize and 
catalyze the self-cleavage of the viral RNA phosphodiester backbone. However, a major obstacle in the medical 
application of the HDV ribozyme is the lack of specificity in the delivery of the ribozyme to defined target cells.
Results: The objective of this study was to determine whether retroviral vectors can deliver the HDV ribozyme into the 
target cells and to elucidate whether HDV ribozyme plays a role in hepatitis B virus (HBV) replication. In our study, the 
transduction of helper-free pseudotyped retrovirus, which showed a broad host range, in human hepatoma cells was 
performed under 2 conditions, that is, in the presence of polymerized human serum albumin (pHSA) and in the 
absence of pHSA. The transduction ability in the presence of pHSA was higher than in the absence of pHSA. Moreover, 
HBsAg and HBeAg levels after transductions with pHSA were significantly lower than those in the absence of pHSA, 
thus indicating that the recombinant retrovirus had HBV-specific cleavage activity and targeted HepG2215 cells.
Conclusions: These data suggest that this system provides a new approach for targeting hepatocytes and has a great 
potential in gene therapy for HBV infection.
Introduction
Hepatitis B virus (HBV) causes acute and chronic infec-
tions of the liver. Acute infections can cause serious ill-
nesses and lead to fatal fulminant hepatitis in
approximately 0.5% of the patients. Chronic infections
may also induce serious consequences leading to untreat-
able hepatocellular carcinoma (HCC) in nearly 25% of the
patients. The number of deaths attributed to hepatocellu-
lar carcinoma caused by HBV infection in the world
probably exceeds 1 million per year [1-3]. Moreover, the
various treatments for chronic infections have had only
limited success [4].
The long-term effects of the recent advanced tech-
niques employed to eliminate the virus, including therapy
with nucleoside analogs and other virus-replication
inhibitors [5,6], are yet to be determined. Since HBV
reverse transcriptase lacks proofreading function, the
virus shows rapid mutagenesis thus creating a large num-
ber of variants, some of which show resistance to antiviral
drugs. This phenomenon is responsible for the low effi-
cacy of the current drugs and the high rates of drug resis-
tance [7,8]. Therefore, there is an urgent need to develop
new anti-HBV drugs.
A ribozyme (Rz) is a small RNA molecule that can act
as an enzyme. Ribozymes catalyze the cleavage of specific
mRNAs in a sequence-specific manner; therefore, they
are attractive therapeutic tools for the inactivation of
both viral RNA and mRNAs associated with human dis-
eases [9,10]. The ribozyme found in the genomic and
antigenomic RNAs of the hepatitis delta virus (HDV)
adopts a novel structural motif that is distinct from the
hammerhead and hairpin motifs of ribozymes found pre-
dominantly in the plant pathogenic RNAs [11,12]. This
HDV ribozyme shows a unique natural ability to function
in human cells.
Viruses have been used to introduce exogenous DNA
sequences into target cells in many gene-therapy strate-
gies for treating genetic diseases, including cancer.
Among the various viral vectors engineered for this pur-
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pose, those based on retroviruses are the best understood
and the most widely used [13,14]. The genomes of the
viral vectors integrate stably into the host cell DNA,
thereby allowing long-term expression of the inserted
therapeutic genes in the host cells. The processes of virus
entry and genome integration do not require viral protein
synthesis. Therefore, all viral genes in the vector genome
can be replaced with exogenous sequences. However, a
major obstacle to the medical application of such vectors
is the lack of specificity in gene delivery to defined target
cells.
In the present study, we designed HDV ribozymes to
cleave HBV-RNA (ayw subtype). The cleavage site was
selected using structural data obtained by computer-
assisted methods [15]. The use of bioinformatics tools
coupled to biochemical assays; RNase H hydrolysis with a
pool of oligonucleotides; and cleavage assays with a pool
of ribozymes. Potential Rz target site was identified by
these procedures and the substrate RNA contained HBV
core region. Rz shows site-specific cleavage of HBV RNA
at certain sites under appropriate conditions in vitro.
However, the intracellular conditions and the factors that
influence ribozyme activity are far more complicated
than the conditions in the extracellular environment;
therefore, there is no data describing whether the HDV
ribozyme can cleave HBV mRNA in vivo. In this study,
the DNA encoding HDV ribozyme was amplified and
c l o n ed  i n  t h e  r e t r o vi r a l  v ec t o r  p MSCV / U 6  ( C l o n t ec h ) ,
and the resultant recombinant vector was named pRz.
Using the calcium phosphate-mediated DNA-transfec-
tion technique, 293T cells were transfected with pRz,
Moloney murine leukemia virus (Mo-MLV), Gag-Pol
expression plasmid (pGAG-POL), and the chimeric enve-
lope expression plasmid (pENV-preS2) [16,17], which
contain the hepatitis B virus PreS2 peptide fused to aa +1
at the N terminus of Env. At 48 h post-transfection, we
obtained helper-free retrovirus stocks with titers of 2.9-4
× 104  cfu/ml, and these stocks were used to infect
HepG2215 cells. The recombinant retrovirus carrying the
HDV ribozyme could bind to hepatocytes in the presence
of polymeric human serum albumin and specifically
cleave the HBV mRNA.
Results
Generation of Retrovirus Stocks
In conjunction with a retroviral vector, 293T cells yielded
infectious, replication-incompetent retrovirus that could
be used to introduce a gene of interest into a wide variety
of mammalian cell types in vitro or in vivo. The transfec-
tion of 293T cells with pRz recon, Moloney murine leuke-
mia virus (MoMLV), Gag-Pol expression plasmid
(pGAG-POL), and the chimeric envelope expression
plasmids--pENV-preS2 or pENV, which encode HBV
preS2-Env chimeric envelope and wild-type ecotropic
envelope, respectively, produced wild-type retrovirus
stocks (titer, 0.9 × 106 cfu/ml) and pseudotyped retrovirus
stocks (titers, 2.9-4 × 104 cfu/ml). The undiluted viral
supernatants were used to infect HepG2215 cells.
Analysis of Helper Virus
We examined the supernatants from the transfected
293T cells to detect contaminating replication-competent
viruses or helper viruses. NIH 3T3 cells were infected
with undiluted supernatants of the retroviral stocks, and
these cells were then passaged for 4 weeks to allow virus
propagation. During each passage, the culture superna-
tants were harvested, filtered, and used to infect fresh
NIH 3T3 cells. These cells were selected in puromycin for
up to 10 days to detect the presence of replication-com-
petent virus harboring the pur gene. No puromycin-resis-
tant colonies were detected at 10 days post-infection.
Inhibition of HBsAg and HBeAg in HepG2215 Cells
The culture medium was analyzed using enzyme linked
immunosorbent assay to determine the HBsAg and
HBeAg concentrations. Figure 1A shows that the pHSA-
mediated HDV ribozyme transfection showed more sig-
nificant inhibition of HBsAg-expression than did trans-
fection without pHSA mediation; the inhibitory effects
were calculated with reference to the negative control
RzNC (Rz with pHSA vs. Rz without pHSA, P < 0.001). In
comparison with RzNC, Rz and pHSA caused a 78.7%
decrease in the extracellular HBeAg levels at 48 h after
treatment; however, in the absence of pHSA, the corre-
sponding value was only 17.3% (Rz with pHSA vs. Rz
without pHSA, P = 0.001)(Figure 1B).
Inhibition of HBV replication in HepG2215 Cells
Cultures with and without retroviruses were maintained
at 37°C for 48 h and then assessed for the presence of viral
DNA in cell lysates. HBV DNA was analyzed quantita-
tively, and the relative rate of HBV replication was deter-
mined. HBV DNA was analyzed using real-time PCR. As
shown in Figure 2, in comparison to the corresponding
values for the negative control Rz, the number of HBV
DNA copies per ml decreased to 2.16 × 106 copies/ml
after ribozyme treatment with pHSA and to 7.26 × 106
copies/ml after ribozyme treatment without pHSA (Rz
without pHSA vs. Rz with pHSA, P < 0.001).
Discussion
The currently available viral vectors for gene therapy lack
host-cell specificity. During the past few years, a series of
different targeting strategies, including cross-linking of
MLV retroviral vectors to target cells using an antibody
bridge [18,19] and genetic modification of Mo-MLV Env
by the addition of single-chain antibody variable frag-
ments [20], have been developed to modify the retroviralWang et al. Virology Journal 2010, 7:61
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envelopes for broad host range. However, such attempts
to redirect retroviruses to specific cells by attaching addi-
tional cell-binding ligands to the ecotropic MLV Env have
met with little success so far. The HBV envelope is com-
posed of 3 related surface (S) proteins. The preS2 mRNA
encodes albumin receptors, which bind to pHSA and
mediate viral attachment to the hepatocytes [21]. In our
previous study, we had constructed a chimeric envelope
expression plasmid pENV-preS2, which express the HBV
preS2 peptide fused to aa +1 at the N-terminus of ENV
protein. After cotransfection of pGAG-POL, pRz, and
chimeric env plasmids into the 293T cells, retrovirus
s t o c k s  w e r e  o b t a i n e d  a t  4 8  h  p o s t - t r a n s f e c t i o n .  T h e s e
pseudotyped vectors infected the normal host NIH 3T3
cells although the efficiency of infection was lesser than
that of the virions with the wild-type ecotropic MoMLV
envelope. In addition, the transduction ability of the
pseudotyped viruses in human hepatoma cells was higher
in the presence of pHSA than in the absence of pHSA,
thereby indicating that pHSA could attach to the hepato-
cyte membranes Thus, pHSA receptor acts as an "inter-
mediate ligand" [16].
Since no helper virus could be detected after 10 days
post-infection, we deduced that the viral stocks obtained
in this study did not contain helper viruses. Here, we
report a significant reduction in the intracellular HBV
DNA concentration in HepG2215 cells, which markedly
decreased after 48 hours of incubation with Rz. Similar
findings have been reported in previous studies [22,23].
The Rz used in this experiment is known to show high
cleavage activity in HBV mRNA. Initially, we tried to
design a series of trans-HDV ribozymes to cleave HBV
mRNA [15]. The substrate RNAs were RNA sequences
from the C region of the HBV genome. The result show
that under the optimized cleavage conditions, ribozyme
specifically cleaved the mRNA of the HBV core gene; fur-
ther, at 90 min, the percentage of the cleaved substrates
increased with time: up to 53%.
The HDV ribozymes are potentially attractive tools for
directed RNA degradation [24]. These ribozymes are nat-
urally active in human cells, and at physiological Mg2+ ion
concentrations, they show the highest cleavage rates
among all known ribozymes [25-27].
In this study, we have shown that the retrovirus-based
Rz could significantly inhibit HBV antigen expression.
Our results show that the extracellular HBsAg and
HBeAg levels after treatment with HDV ribozyme were
lower than those after treatment with the negative con-
trol ribozyme. HBsAg and HBeAg are translated from
preS/S mRNA and precore mRNA, respectively.
Although HBeAg is translated from precore mRNA, the
preC and C regions are in the same open reading frame
(ORF). In addition, the entire 2.1-kb mRNA encoding
HBsAg comprises overlapping reading frames, and this
sequence is contained within the 3.5-kb mRNA sequence
encoding HBeAg. Since Rz could specifically cleave the C
region RNA, HBeAg expression was suppressed; thus, the
HBeAg and HBsAg levels decreased. We also observed
downregulation of the number of HBV DNA copies/ml
Figure 1 Inhibition of HBsAg and HBeAg secretion in HepG2215 
cell supernatants by HDV ribozyme with or without pHSA. A: 
HepG2215 cells were transduced with a retrovirus carrying the HDV ri-
bozyme with and without pHSA. At 48 hours after infection, the super-
natants were collected, and ELISA was performed to detect HBsAg. The 
level of HBsAg was significantly decreased with pHSA (P < 0.001). The 
values are the mean ± S.D. values of 3 independent tests; B: ELISA de-
tecton of HBeAg. Rz could significantly inhibit HBeAg expression with 
pHSA (P = 0.001).
Figure 2 HBV DNA copies in HepG2215 cells. HBV DNA was extract-
ed and real-time PCR was performed (p < 0.001).Wang et al. Virology Journal 2010, 7:61
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after incubation with Rz-containing retrovirus comparing
both ribozyme negative control and empty vector, instead
of intrinsic effect of transduction. The Rz inhibited HBV
pregenomic RNA, which is reverse transcribed to viral
DNA; therefore, HBV replication is impeded. Hence,
HBV is assumed to be susceptible to Rz at both the post-
transcription and replication levels. These results are in
a c c o r d a n c e  w i t h  t h o s e  o b t a i n e d  b y  L i  e t  a l  [ 2 8 ] ,  w h o
found that a dual-shRNA expression vector (AAV-157i/
1694i), which coexpressed 2 shRNAs, targeted the S and
X genes of HBV and reduced the levels of HBsAg,
HBeAg, and HBV DNA by 87% ± 4%, 80.3% ± 2.6%, and
86.2% ± 7% respectively, at 8 days post-transduction. In a
mouse model of prophylactic treatment, HBsAg and
HBeAg were reduced to undetectable levels, and the
serum HBV DNA level showed at least a 100-fold reduc-
tion.
Conclusions
The HBV-specific HDV ribozyme can catalyze sequence-
specific HBV mRNA degradation and suppress HBV rep-
lication. The retrovirus carrying Rz has the potential for
use in gene therapy for HBV infection.
Materials and methods
Cell Culture
The following cell lines were grown in Dulbecco's Modi-
f i e d  E a g l e ' s  M e d i u m  ( D M E M ,  G i b c o ,  U S A )  s u p p l e -
mented with 10% fetal bovine serum (Gibco, USA): 293T
(ATCC CRL-11268), NIH 3T3 (ATCC CRL-1658),
HepG2215, and human embryonic kidney cells (HEK)
(ATCC CRL-1573). All cells were cultured in 5% CO2 at
37°C.
Construction of the pRz Recon
The HDV ribozyme targeting the HBV core-gene
sequence was synthesized. The sequences of ribozyme
were: Rz sense: 5'-CGCGGGCCCAGCTRGGGTCCAC-
CTCCTCGCGGTGGTGGCTGGG-3' (Apa  I) and Rz
antisense:5'-CGCGAATTCTCGACCCAGCCACCAC-
CGCGAGGAGGTGGACCCA-3' (EcoR  I). Then, this
sequence was cloned into the pGEM-T vector (Promega)
and subcloned in the multiple cloning sites of the retrovi-
ral plasmid pMSCV/U6, which was digested with the
same restriction enzymes (Figure 3); the resultant recom-
binant recon was called the pRz recon. The ribozyme of a
random sequence unrelated to HBV was amplified with
PCR and cloned into pMSCV/U6 to obtain pRzNC,
which was considered as the negative control. All
ribozyme sequences were confirmed by sequencing.
Retrovirus packaging, Infection, and Determination of Viral 
Titer
The 293T cells were transfected by overnight calcium
phosphate treatment on 10-cm dishes seeded on the pre-
vious day, which yielded a maximum of 70% confluence/
plate on the day of transfection. Retroviruses were gener-
ated by cotransfection of 293T cells with 10 μg of pRz, 20
μg of pGAG-POL, and 10 μg of pENV-preS2. The trans-
fected cells were incubated for 15-17 h after which the
medium was replaced with 5 ml of fresh medium. The
viral supernatants were harvested 48 h after transfection,
filtered through 0.45 μm filters, and titered by serial dilu-
tion on NIH 3T3 cells [29].
NIH 3T3 cells were plated onto 6-well culture dishes at
a density of 1-2 × 105 cells/well on the day before infec-
tion. A fixed volume (1 ml) of the undiluted supernatant
and 8 μg/ml polybrene (Sigma) was added to each well,
and the wells were incubated for 2 h, which was followed
by the addition of 1 ml of fresh medium. Twenty four
hours later, the cells were diluted (1:4) and seeded onto 5-
cm dishes. The viral titer was determined by selection
with 800 μg/ml puromycin. The medium was replaced
every 3 or 4 days, and the resistant colonies were counted
10-15 days post-infection by fixing and staining with 0.3%
crystal violet in 70% methanol. The viral titer was deter-
mined by multiplying the total number of puromycin-
resistant colonies by 2, which was performed to account
for the 2-fold increase in the cells during the infection
period, and by considering the 1:4 dilutions.
Helper Virus Assays
Transfections in 293T cells were performed using the
protocols described above, and undiluted viral superna-
tants were used to infect NIH 3T3 cells. All infections
Figure 3 Construction of expression plasmids. The expression plas-
mid for the chimeric envelope was assembled by cloning HBV preS2 
and ENV coding sequences to multiple cloning sites of the eukaryotic 
expression plasmid pcDNA3.1(-). The insertion sites are Hind III and XhoI 
in mutated ENV. The pGAG-POL and pRz recons expressed Moloney 
murine leukemia virus (Mo-MLV), Gag-Pol protein, and HDV ribozyme, 
respectively. The ENV and GAG-POL expression plasmid contains an 
MoMLV CMV-driven promoter, while Rz is an MoMLV LTR promoter. All 
plasmids contain SV40 origins of replication. SP, signal peptide.Wang et al. Virology Journal 2010, 7:61
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were performed in the presence of 8 μg/ml polybrene.
The NIH 3T3 cells were passaged every 4-5 days, and the
culture supernatants were filtered and used to infect fresh
NIH 3T3 cells. These cells were selected in puromycin for
up to 10-15 days and used to assay for the presence of
replication-competent viruses.
Analysis of Ribozyme in NIH 3T3 Cells
Transfection and infection were performed on 293T and
NIH 3T3 cells, respectively, by using the methods
described above. Genomic DNA from infected cells was
extracted using the DNeasy kit (QIAGEN) according to
the manufacturer's instructions. The ribozyme was
detected by PCR. The primers P1 and P2 were used as
described above.
Enzyme linked immunosorbent assay (ELISA) and Real-time 
PCR Assays
On the day before infection, HepG2215 cells were seeded
in 24-well tissue culture dishes at a density of 3 × 104
cells/well. A total of 250 μl of the undiluted supernatants
was added to each well along with 8 μg/ml of polybrene
and incubated for 2 h; the incubation was followed by the
addition of 1 ml of fresh medium. Each experiment was
performed in triplicate. For pHSA-mediated experi-
ments, pHSA (5 μg/ml) was added to the culture
medium, which was followed by incubation at 4°C for 4 h
and viral infection. The supernatants and cells were har-
vested once everyday for 4 days. The levels of hepatitis B
surface antigen (HBsAg) and hepatitis B e antigen
(HBeAg) were determined using licensed ELISA kits
(Shanghai Rongsheng Biotech Co. Ltd.)according to the
manufacturer's instructions. Genomic DNA was
extracted from the infected cells by using the QIAGEN
DNeasy kit. Real-time (RT) quantitative PCR was per-
formed using the following gene-specific primers: P3, -
5'-AGAATCCTCACAATACCGCAGAGT-3'; P4, - 5'-
CACACGGTAGTTCCCCCTAGAA-3'; and probe: P5, -
5'-FAM-AGACTCGTGGTGGACTTCTCTCAAT-
TAMRA-3' [30]. The standards were obtained using the
above primers. For RT-PCR, the 20-μL reaction mixture
contained 1 μL of genomic DNA or standard DNA, 2 μL
of 10 × PCR reaction buffer, 20 mmol of each dNTP, 5
μmol of the primers, 2.5 μmol of the probe, and 1 U of
hot-start DNA polymerase (TAKARA). All amplification
reactions were performed in triplicate. The following
PCR cycle was used: initial denaturation at 95°C for 30 s
followed by 40 cycles of denaturation at 95°C for 5 s and
annealing at 60°C for 34 s. In each cycle, fluorescence
readings were recorded at 60°C. Real-time PCR was done
on the 7500 Real-Time PCR System (Applied Biosys-
tems).
Statistical Analysis
Paired-samples  t  test was performed using SPSS 17.0.
The differences were considered statistically significant
when P values were less than 0.05.
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